[go: up one dir, main page]

HRP20240473T1 - Compositions for the treatment of pathogenic infections - Google Patents

Compositions for the treatment of pathogenic infections Download PDF

Info

Publication number
HRP20240473T1
HRP20240473T1 HRP20240473TT HRP20240473T HRP20240473T1 HR P20240473 T1 HRP20240473 T1 HR P20240473T1 HR P20240473T T HRP20240473T T HR P20240473TT HR P20240473 T HRP20240473 T HR P20240473T HR P20240473 T1 HRP20240473 T1 HR P20240473T1
Authority
HR
Croatia
Prior art keywords
acid
preparation
anhydrous
oxidizing
liquid medium
Prior art date
Application number
HRP20240473TT
Other languages
Croatian (hr)
Inventor
Walter SCHAUB
Original Assignee
Walter SCHAUB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter SCHAUB filed Critical Walter SCHAUB
Priority claimed from PCT/EP2018/061607 external-priority patent/WO2018202897A1/en
Publication of HRP20240473T1 publication Critical patent/HRP20240473T1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (1)

1. Farmaceutski pripravak koji sadrži kruti pripravak bez otapala,1. Pharmaceutical preparation containing a solid preparation without solvent, koji sadrži jednu ili više oksidirajućih komponenti odabranih od natrijevog, kalijevog, magnezijevog ili kalcijevog hipoklorita, klorita ili klorata, artemisinin oksidirajuće komponente,containing one or more oxidizing components selected from sodium, potassium, magnesium or calcium hypochlorite, chlorite or chlorate, artemisinin oxidizing component, koji sadrži bezvodnu kiselinu odabranu od bezvodne limunske kiseline, glukonske kiseline, mliječne kiseline, oksalne kiseline, vinske kiseline, jabučne kiseline, askorbinske kiseline, stearinske kiseline ili smjese dviju ili više navedenih kiselina,which contains an anhydrous acid selected from anhydrous citric acid, gluconic acid, lactic acid, oxalic acid, tartaric acid, malic acid, ascorbic acid, stearic acid or a mixture of two or more of the aforementioned acids, pri čemu se navedena jedna ili više oksidirajućih komponenti mogu dispergirati ili otopiti u vodenom tekućem mediju, iwherein said one or more oxidizing components can be dispersed or dissolved in an aqueous liquid medium, and pri čemu disperzija ili otapanje navedene jedne ili više oksidirajućih komponenti u vodenom tekućem mediju koji sadrži bezvodnu kiselinu sadržanu u krutom pripravku bez otapala, rezultira oslobađanjem ili stvaranjem hipokloritnog iona ili hipokloraste kiseline, kloritnog iona ili kloridne kiseline, kloratnog iona ili klorne kiseline, molekularnog ili ionskog klorovog dioksida unutar vodenog tekućeg medija,wherein the dispersion or dissolution of said one or more oxidizing components in an aqueous liquid medium containing anhydrous acid contained in a solid preparation without solvent results in the release or formation of hypochlorite ion or hypochlorous acid, chlorite ion or hydrochloric acid, chlorate ion or chloric acid, molecular or of ionic chlorine dioxide in an aqueous liquid medium, pri čemu navedeni pripravak sadrži količinu oksidirajuće komponente koja ne prelazi oko 5% m/m ukupne težine pripravka, za apsorpciju kroz usta ili bukalnu šupljinu toplokrvnog sisavca,wherein said preparation contains an amount of oxidizing component that does not exceed about 5% m/m of the total weight of the preparation, for absorption through the mouth or buccal cavity of a warm-blooded mammal, pri čemu je navedena jedna ili više oksidirajućih komponenti blisko pomiješana s bezvodnom kiselinom, iwherein said one or more oxidizing components are intimately mixed with the anhydrous acid, and naznačen time što je navedeni farmaceutski pripravak predviđen kao oralni oblik doziranja u obliku topive pastile za zadržavanje u ustima ili bukalnoj šupljini toplokrvnog subjekta sisavca, za oslobađanje navedene jedne ili više oksidirajućih komponenti u vodeni tekući medij koji sadrži bezvodnu kiselinu, istodobnim oslobađanjem navedene bezvodne kiseline u sadržaj sline bukalne šupljine i time omogućava izravnu sistemsku apsorpciju oksidirajuće komponente kroz usta ili bukalnu šupljinu toplokrvnog subjekta sisavca,characterized in that the said pharmaceutical preparation is intended as an oral dosage form in the form of a soluble lozenge for retention in the mouth or buccal cavity of a warm-blooded mammal subject, for the release of said one or more oxidizing components into an aqueous liquid medium containing anhydrous acid, with the simultaneous release of said anhydrous acid into the saliva content of the buccal cavity and thereby enables direct systemic absorption of the oxidizing component through the mouth or buccal cavity of a warm-blooded mammalian subject, u kojoj pripravak sadrži udio natrijevog bikarbonata ili kalijevog bikarbonata ili njihove kombinacije, koji je veći od oko 30% m/m ukupne težine pripravka.in which the preparation contains a proportion of sodium bicarbonate or potassium bicarbonate or their combination, which is greater than about 30% m/m of the total weight of the preparation.
HRP20240473TT 2017-05-04 2018-05-04 Compositions for the treatment of pathogenic infections HRP20240473T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH599202017 2017-05-04
PCT/EP2018/061607 WO2018202897A1 (en) 2017-05-04 2018-05-04 Compositions and treatment procedures for the treatment of pathogenic infections
EP18723791.2A EP3618826B1 (en) 2017-05-04 2018-05-04 Compositions for the treatment of pathogenic infections

Publications (1)

Publication Number Publication Date
HRP20240473T1 true HRP20240473T1 (en) 2024-07-05

Family

ID=91668307

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240473TT HRP20240473T1 (en) 2017-05-04 2018-05-04 Compositions for the treatment of pathogenic infections

Country Status (4)

Country Link
ES (1) ES2975418T3 (en)
HR (1) HRP20240473T1 (en)
RS (1) RS65512B1 (en)
SM (1) SMT202400184T1 (en)

Also Published As

Publication number Publication date
ES2975418T3 (en) 2024-07-05
SMT202400184T1 (en) 2024-07-09
RS65512B1 (en) 2024-06-28

Similar Documents

Publication Publication Date Title
AR052173A1 (en) SOLID DOSAGE FORM INCLUDING A PROTONIC PUMP INHIBITOR AND A SUSPENSION OBTAINED FROM THE SAME
RU2010148556A (en) COMPOSITIONS CONTAINING TIN CHLORIDE
PE20120361A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING CRYSTALLINE FORMS OF ACID 6- (3-CHLORO-2-FLUOROBENZYL) -1 - [(S) -1-HYDROXIMETHYL-2-METHYLPROPYL] -7-METOXY-4-OXO-1,4-DIHYDROQUINOLINE- 3-CARBOXYL
IL179718A0 (en) Pharmaceutical composition containing irbesartan
PE20180522A1 (en) ORODISPERSABLE DOSING UNIT CONTAINING A STETROL COMPONENT
MX2008000087A (en) Rapidly absorbing oral formulations of pde5 inhibitors.
PE20091441A1 (en) ORAL CARE PRODUCT AND METHODS TO USE AND MAKE THE SAME
PE20060505A1 (en) PHARMACEUTICAL COMPOSITION OF 4 {4- [3- (4-CHLORO-3-TRIFLUOROMETHYLPHENYL) -UREIDO] -3-FLUORO-PHENOXY} -PYRIDINE-2-CARBOXYL ACID IN THE FORM OF A SOLID DISPERSION USEFUL IN HYPERPERATIVE DISORDERS
JP2008533183A5 (en)
ES2708623T3 (en) Oral and / or oral composition in the form of a thin film of a weakly soluble active principle, its method of preparation and its use
DE602005021770D1 (en) INDOLE-1-YL-ACETIC DERIVATIVES
CN102133155A (en) Skin cleaning agent having excellent water solublility
JP2011511793A5 (en)
EA201991147A1 (en) TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM USING sGC STIMULANTS
PE20090371A1 (en) NEVIRAPIN FORMULATION OF PROLONGED RELEASE
HRP20240473T1 (en) Compositions for the treatment of pathogenic infections
JP2018511644A5 (en)
MX2021001145A (en) Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome.
AU2018263059A1 (en) Compositions and treatment procedures for the treatment of pathogenic infections
ZA201707673B (en) Slow dissolving hypochlorite containing tablet
BR112015020019A2 (en) tablet for the treatment of sore throat, hoarseness and associated dry cough and inflammatory diseases of the oral and pharyngeal cavity
JP2015528515A5 (en)
HRP20210890T1 (en) PHARMACEUTICAL FORMULATION WITH EGFR ANTIBODY PREPARATION
TW200505855A (en) Indol-4-yl sulfonamide derivatives, their reparation and their use in medicaments
HRP20201436T1 (en) Macrogols for application to the mucosa, and therapeutic uses thereof